ArticleGerman medical science : GMS e-journal2014
Which adverse effects influence the dropout rate in selective serotonin reuptake inhibitor (SSRI) treatment? Results for 50,824 patients.
Article in German medical science : GMS e-journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- What is the impact of antidepressant side effects on medication adherence among adult patients diagnosed with depressive disorder: A systematic review.Journal of psychopharmacology (Oxford, England) · 2024Pooled it
- Study adherence in a tDCS longitudinal clinical trial with people with spinal cord injury.Spinal cord · 2018Trial
- Worsening Anxiety, Irritability, Insomnia, or Panic Predicts Poorer Antidepressant Treatment Outcomes: Clinical Utility and Validation of the Concise Associated Symptom Tracking (CAST) Scale.The international journal of neuropsychopharmacology · 2018Trial
- The Feasibility and Efficacy of a Brief Integrative Treatment for Adults With Depression and/or Anxiety: A Randomized Controlled Trial.Journal of evidence-based integrative medicineTrial
- Mental Disorders as Risk Factors for New Onset Cardiovascular Diseases.Biomedicines · 2026Review
- Antidepressant prescribing patterns and patient-reported adverse effects: a cross-sectional study from Pakistan.Annals of general psychiatry · 2026Article
- Clinical Study to Evaluate Drug Interactions of Cannabidiol with Citalopram and Morphine in Healthy Adults.Clinical pharmacology and therapeutics · 2026Article
- The short-term effectiveness of antidepressants in a transdiagnostic sample and determinants of side effects and medication nonadherence: an observational study.Frontiers in psychiatry · 2025Article
- Drug-Drug Interactions of Selective Serotonin Reuptake Inhibitors: A Pharmacovigilance Study on Real-World Evidence from the EudraVigilance Database.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Discontinuation of Antidepressants in Older Adults: A Literature Review.Therapeutics and clinical risk management · 2023Review
- Examining the Use of Antidepressants for Adolescents with Depression/Anxiety Who Regularly Use Cannabis: A Narrative Review.International journal of environmental research and public health · 2022Review
- Risks of Digestive System Side-Effects of Selective Serotonin Reuptake Inhibitors in Patients with Depression: A Network Meta-Analysis.Therapeutics and clinical risk management · 2022Review
- Antidepressant Shugan Jieyu Capsule Alters Gut Microbiota and Intestinal Microbiome Function in Rats With Chronic Unpredictable Mild Stress -Induced Depression.Frontiers in pharmacology · 2022Article
- Activation of WNT and CREB signaling pathways in human neuronal cells in response to the Omega-3 fatty acid docosahexaenoic acid (DHA).Molecular and cellular neurosciences · 2019Article
- Sex Differences in Reported Adverse Drug Reactions of Selective Serotonin Reuptake Inhibitors.Drug safety · 2018Article
- Article
- Utilizing yeast chemogenomic profiles for the prediction of pharmacogenomic associations in humans.Scientific reports · 2016Article
- Selective serotonin reuptake inhibitors and cardiovascular events: A systematic review.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2016Review
- Do sleep disturbances and psychotic-like experiences in adolescence share genetic and environmental influences?Journal of abnormal psychology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNowadays, selective serotonin reuptake inhibitors (SSRIs) are the most frequently prescribed antidepressants due to their superior clinical efficacy, effectiveness, tolerability, and safety as compared to tricyclic antidepressants or monoamino oxidase inhibitors. However, despite these advantages SSRIs are still associated with a number of adverse drug reactions, especially in the early stages of treatment, which may lead to premature discontinuation of therapy in some cases. The aim of the present study was to assess the most common adverse drug reactions of SSRIs as well as their impact on dropout rate in a large study population. PATIENTS AND
methodsData for 50,824 patients treated for major depressive disorder with SSRIs for the first time was accessed via the Disease Analyzer database (IMS Health, Germany), providing information on SSRI adverse drug reactions and their influence on premature treatment discontinuation calculated by regression analysis. The presence of certain co-morbidities was also registered.
resultsThe mean age was 54.5 ± 19 years, two-thirds of the study population being female. The adverse effects mentioned most frequently were: "discomfort" of the digestive system (10%), sleep disorders (8.6%), and heart rhythm disorders (4%); however, these were of tolerable severity as they did not significantly influence the dropout rate. Contrary to that, somnolence and younger age (≤50 years) in particular increased the chance of premature treatment discontinuation, while patients suffering from cardiovascular risk factors or osteoporosis tended to adhere to the therapy.
conclusionsOverall, there is high tolerability for early SSRI treatment, whereas the occurrence of somnolence leads to discontinuation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.